medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 6

<< Back Next >>

Med Int Mex 2018; 34 (6)

Administration of omalizumab in Mexican patients diagnosed with moderate-severe non-atopic asthma

Herrera-García JC, Galindo-Solano R, Arellano-Montellano EI, Jaramillo- Arellano LE, Espinosa-Arellano A

Language: Spanish
References: 26
Page: 833-839
PDF size: 463.27 Kb.


ABSTRACT

Objective: To determine the clinical improvement in patients diagnosed with moderate-severe non-atopic asthma in treatment with omalizumab.
Material and Method: A prospective and observational study was made from January 1st 2017 to January 1st 2018 in adult patients who, despite daily treatment with or without maintenance oral corticosteroids, had uncontrolled moderate to severe nonatopic asthma; patients were assigned to receive omalizumab at doses of IgE levels. The primary endpoint was the change in the clinical and functional parameters of the patients by means of Asthma Control Test.
Results: There were included 20 patients. After 52 weeks of administration of omalizumab they showed a moderate increase in FEV1 and in clinical and functional parameters. The symptomatic improvement of the patients was mainly considered by an increase of 10 to 20 points in Asthma Control Test. Good tolerance to the drug was also observed, without any serious adverse effects, as well as improvement in the quality of life of the patients.
Conclusions: Omalizumab has a therapeutic role in moderate to severe non-atopic asthma. Our results support the clinical efficacy of omalizumab in Mexican non-atopic asthmatic patients.


REFERENCES

  1. Borriello EM, Vatrella A. Does non-allergic asthma still exist? Shortness of Breath 2013;2(2):55-60.

  2. Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966;97(1):75-85.

  3. Brown WG, Halonen MJ, Kaltenborn WT, Barbee RA. The relationship of respiratory allergic, skin test reactivity and serum IgE in a community population sample. J Allergy Clin Immunol 1979;63(5):328-335.

  4. Sunyer J, Antó JM, Castellsague J, Soriano JB, Roca J. Total serum IgE is associated with asthma independently of specific IgE levels. The Spanish Group of the European Study of Asthma. Eur Resp J Sep 1996;9(9):1880-1884.

  5. Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated in non-allergic individuals. Eur Resp J Oct 2000;16(4):609-614.

  6. Domingo C. Overlapping effects of new monoclonal antibodies for severe asthma. In: Drugs. Springer International Publising AG; 2017. DOI: 10.1007/s40265-017-0810-5.

  7. Herrera-García JC, Sánchez-Casas GA, Arellano-Jaramillo LE, Lechuga-Hernández S, et al. Omalizumab in the treatment of moderate to severe persistent asthma in the context of allergic and non-allergic asthma. Med Int Méx 2015;31:693-700.

  8. Pillai P, Chan Y-C, Wu S-Y, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Resp J 2016;48:1593-1601.

  9. Menzella F, Piro R, Facciolongo N, et al. Long-term benefits of omalizumab in patient with severe non-allergic asthma. Allergy Asthma Clin Immunol 2011;7:9.

  10. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin test reactivity to allergens. N Engl J Med Feb 1989;320(5):271- 277.

  11. Humbert M, Menz G, Ying S, et al. The Immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: More similarities than differences. Immunology Today 1999;20:528-533.

  12. Humbert M, et al. High affinity IgE receptor bearing cells in bronchial biopsies from atopic and non-atopic asthma. Am J Respir Crit Care Med Jun 1996;153(6):1931-1937.

  13. Ying S, et al. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and non-atopic asthma. J Allergy Clin Immunol Jan 2007;119(1):213-218.

  14. Mouthuy J, Detry B, Sohy C, Pirson F, Pilette C. Presence in sputum of functional dust mite specific IgE antibodies in intrinsic asthma. Am J Respir Crit Care Med 2011 Jul 15;184(2):206-214.

  15. Navines-Ferrer A, Serrano-Candelas E, Molina Molina GJ, Martin M. IgE-related chronic diseases and anti-IgE based treatments. Hindawi Publising Corporation. J Immunol Res 2016:1-12. http://dx-doi.org/10-1155/2016/8163803.

  16. Herrera J. Use of omalizumab In Mexican patients with a diagnosis of moderate to severe non-atopic asthma: ATS journals in American Thoracic Society 2018 International Conference. Thematic Poster Session- San Diego Convention Center.

  17. Herrera García JC, et al. Use of omalizumab as treatment in patients with moderate and severe non-atopic asthma and associated with asthma- COPD overlap syndrome (ACOS) in asthma diagnosis and management. IntechOpen, DOI: 10.5772/intechopen.73904. July 4th 2018.

  18. Gaga M, Zervas E, Humbert M. Targeting immunoglobulin E in non-atopic asthma: crossing the red line? Eur Resp J 2016;48:1538-1540. DOI: 10.1183/13993003.01797-2016.

  19. Herrera J, et al. Successful use of omalizumab as a patient treatment with chronic rhinosinusitis, nasal polyps and severe asthma. In: National Congress of Pneumology: 17- 21 April 2017. Puebla, Puebla City.

  20. Garcia G, Magnan A, Chiron R, et al. A proof of concept, randomized, controlled trial of omalizumab in patients with severe, difficult to control, nonatopic asthma. Chest 2013;144:411-419.

  21. Lynch JP, Mazzone SB, Rogers MJ, Arikkatt JJ, Loh Z, Pritchard AL, Upham JW, Phipps S. The plasmacytoid dendritic cell: at the cross–roads in asthma. Eur Respir J 2014;43:264-275.

  22. Van den Berge M, Pauw RG, de Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (omalizumab) in a patient with severe asthma and negative skin prick test results. Chest 2011;139:190-193.

  23. Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM. Effectiveness of omalizumab in non-allergic severe asthma. J Biol Reg Homeostatic Agents 2013;27:45-53.

  24. De Llano LP, et al. Effects of omalizumab in non-atopic asthma: Results from a Spanish multicenter registry. J Asthma 2013;50:296-301.

  25. Herrera J, et al. Successful use of omalizumab in non atopic severe asthma In: National Congress of Pneumology. 17-21 April 2017. City of Puebla.

  26. Kutlu A, Demirer E, Ozturk S, Gunes A, Kartal O, Sezer O, Kartaloglu Z. Can anti-IgE treatment be used in non-atopic asthma patients: thoughts of a case about the role of IgE in asthma. Gülhane Tıp Dergisi 2014;56:46-44. Doi: 10.5455/ gullhane.11713




2020     |     www.medigraphic.com